
Desmopressin (DDAVP) – Polish
Also Available In: English, Spanish, French, Arabic, Russian, Simplified Chinese This is not an official WFH translation. This resource has been
Year: 2016
Language: English
This resource is also available in: Arabic French Russian Spanish Simplified Chinese
Author(s): World Federation of Hemophilia
Format: Document
This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Polish
Desmopressin (DDAVP) may be the treatment of choice for patients with mild or moderate hemophilia A and type 1 von Willebrand disease (VWD). This Fact Sheet presents essential information about this synthetic medicine which costs much less than plasma products or recombinant clotting factor concentrates, carries no risk of transmission of viral infections, and is on the World Health Organization’s (WHO) Model List of Essential Medicines (EML).

Also Available In: English, Spanish, French, Arabic, Russian, Simplified Chinese This is not an official WFH translation. This resource has been

A summary of discussions held at the Ninth WFH Global Forum on Research and Treatment Products for Bleeding Disorders which

Quality data are extremely useful in advocating for better care for people with bleeding disorders. This Fact Sheet introduces the

This guide explains how a national procurement system of factor concentrates can help to ensure that people with bleeding disorders

A summary of discussions held at the World Federation of Hemophilia’s Global Forum on the Safety and Supply of Hemophilia

A description of the mechanism of action of fibrinolytic inhibitors and their use in the treatment of inherited bleeding disorders